Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Target Price at $79.75

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $79.75.

ANIP has been the subject of a number of research analyst reports. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target on the stock. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective for the company. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th.

Remove Ads

ANI Pharmaceuticals Stock Down 1.3 %

ANIP stock traded down $0.89 during midday trading on Friday, hitting $65.12. 383,752 shares of the company's stock were exchanged, compared to its average volume of 266,954. The firm has a 50 day moving average price of $62.15 and a 200-day moving average price of $59.00. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.00. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -118.40 and a beta of 0.49. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock valued at $191,776 in the last quarter. Corporate insiders own 12.70% of the company's stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in ANI Pharmaceuticals by 17,558.4% during the 1st quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company's stock valued at $6,360,000 after purchasing an additional 94,464 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in ANI Pharmaceuticals by 41.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company's stock valued at $2,648,000 after buying an additional 13,948 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in ANI Pharmaceuticals during the fourth quarter worth about $1,128,000. Rafferty Asset Management LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter worth about $200,000. Finally, ProShare Advisors LLC raised its holdings in shares of ANI Pharmaceuticals by 29.0% in the 4th quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company's stock worth $361,000 after purchasing an additional 1,469 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.